Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study by Marcello Tiseo, Corrado Ficorella, Andrea Ardizzoni, Carlo Genova, Francesca Mazzoni, Giuseppe Lamberti, Luca Boni, Ida Colantonio, Alessandro Leonetti, Saverio Cinieri, Andrea Bonetti, Michele Tognetto, Federica Bertolini, Alessandro Follador, Elisa Andrini, Antonio Frassoldati, Francesco Gelsomino, Giulia Pasello, Karim Rihawi, Ferdinando Riccardi, Donatella Giardina, Matteo Brighenti

Get full text

BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature by Marianna Peroni, MD, Alessandro Leonetti, MD, PhD, Roberta Minari, MSc, PhD, Michela Verzè, MSc, Letizia Gnetti, MD, Lorena Bottarelli, MSc, PhD, Cinzia Azzoni, MSc, PhD, Marco Galaverni, MD, Nicola Simoni, MD, Gabriele Missale, MD, Elisabetta Biasini, MD, Marcello Tiseo, MD, PhD

Get full text

Body composition derangements in lung cancer patients treated with first‐line pembrolizumab: A multicentre observational study by Ilaria Trestini, Lorenzo Belluomini, Alessandra Dodi, Marco Sposito, Alberto Caldart, Dzenete Kadrija, Luca Pasqualin, Silvia Teresa Riva, Ilaria Mariangela Scaglione, Daniela Tregnago, Alice Avancini, Jessica Insolda, Linda Confortini, Miriam Casali, Jessica Menis, Emanuele Vita, Marco Cintoni, Marco Todesco, Gianluca Milanese, Isabella Sperduti, Mirko D'Onofrio, Marco Infante, Marcello Tiseo, Maria Cristina Mele, Giampaolo Tortora, Michele Milella, Emilio Bria, Sara Pilotto

Get full text